Venous thromboembolism (VTE) is the cause of significant morbidity and mortality and may lead to other complications, including recurrent VTE and long-term postthrombotic syndrome. Venous thromboembolism represents a huge health economic burden of nearly 500 million dollars/year in the United States. Without adequate prophylaxis, patients undergoing major orthopedic surgery are at high risk of ...

‘Pharmacoeconomics’ is a new (and not altogether elegant) word; but economic interest in drug and other treatments of health problems is much older. Pharmacoeconomics is a sub-discipline of the field of health economics, which itself is a relatively new sub-discipline of economics, only formerly appearing in the economics scientific literature since the 1960s. Pharmacoeconomics is the descripti...

There are important challenges in the application of cost-effectiveness analysis results in the real world that highlight the great divide between academic research and practical application. The difficulty is magnified in cancer because of the intense emotions it raises and their influence on decision making, impacting treatment funding decisions. Nevertheless, the potential for costeffectiven...

I n Canada throughout the 1990s, inhaled corticosteroids (ICS) have been the treatment of choice, and we continue to view ICS as the mainstay of treatment for persistent asthma in children, except for those whose disease is so mild that they only require infrequent, as-needed 2-agonist treatment.1 Corticosteroid dosage should continue to be individualized, and the minimum effective dose should ...

Although the information about medication given in this book has been carefully checked, the author and publisher accept no liability for the accuracy of this information. In every individual case the user must check such information by consulting the relevant literature. This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specific...

BACKGROUND: In 1990, annual costs of the diagnosis and treatment of cancer reached nearly $100 billion and currently constitutes approximately 10% of health care expenditures in the United States. As new and often more expensive therapies for cancer treatment become available, the health care decision-maker must consider the cost effectiveness of the therapy. METHODS: Key principles of economic...

Pharmacoeconomics is the description and analysis of the costs of drug therapy to healthcare systems and society. Pharmacoeconomics is a sub-discipline of the field of health economics, which itself is a relatively new sub-discipline of economics, only formerly appearing in the economics scientific literature since the 1960s. The importance of pharmacoeconomic information to healthcare decision...